Role of Smac/DIABLO in cancer progression

Second mitochondria-derived activator of caspase/direct inhibitor of apoptosis-binding protein with low pI (Smac/DIABLO) is a proapoptogenic mitochondrial protein that is released to the cytosol in response to diverse apoptotic stimuli, including commonly used chemotherapeutic drugs. In the cytosol,...

ver descrição completa

Detalhes bibliográficos
Autores: VILMA ARACELI MALDONADO LAGUNAS, GISELA CEBALLOS CANCINO, JUAN PABLO REYES GRAJEDA, JORGE MELÉNDEZ ZAJGLA
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2008
País:México
Recursos:Instituto Nacional de Medicina Genómica
Repositorio:Repositorio del Instituto Nacional de Medicina Genómica
Idioma:inglés
OAI Identifier:oai:repositorio.inmegen.gob.mx:178
Acesso em linha:http://repositorio.inmegen.gob.mx/record/178
Access Level:acceso abierto
Palavra-chave:info:eu-repo/classification/cti/3
Descrição
Resumo:Second mitochondria-derived activator of caspase/direct inhibitor of apoptosis-binding protein with low pI (Smac/DIABLO) is a proapoptogenic mitochondrial protein that is released to the cytosol in response to diverse apoptotic stimuli, including commonly used chemotherapeutic drugs. In the cytosol, Smac/DIABLO interacts and antagonizes inhibitors of apoptosis proteins (IAPs), thus allowing the activation of caspases and apoptosis. This activity has prompted the synthesis of peptidomimetics that could potentially be used in cancer therapy. For these reasons, several authors have analyzed the expression levels of Smac/DIABLO in samples of patients from different tumors. Although dissimilar results have been found, a tissue-specific role of this protein emerges from the data. The objective of this review is to present the current knowledge of the Smac/DIABLO role in cancer and its possible use as a marker or therapeutic target for drug design.